β-defensin 40 Inhibitors
β-Defensin 40 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of β-defensin 40, a small cationic peptide that is part of the defensin family. Defensins are known for their role in the innate immune system, particularly in their antimicrobial properties against bacteria, viruses, and fungi. β-Defensin 40, a member of this family, is encoded by the DEFB140 gene in humans and exhibits distinct structural features such as a β-sheet-rich fold stabilized by three intramolecular disulfide bonds. These inhibitors function by binding to specific sites on the β-defensin 40 peptide, thereby preventing its interaction with target microorganisms or modulating its immunomodulatory functions. The interaction between the inhibitors and β-defensin 40 typically involves a combination of hydrophobic interactions and hydrogen bonding, which ensures specificity and high binding affinity.
The development of β-defensin 40 inhibitors is largely guided by a deep understanding of the structural biology of β-defensins and their complex mechanisms of action at the molecular level. The inhibitors are designed to exploit the unique structural motifs and electrostatic characteristics of β-defensin 40, often employing techniques such as computational modeling, high-throughput screening, and rational drug design to identify and optimize effective compounds. Structural analogs, small molecules, peptides, or peptidomimetics can serve as effective inhibitors, each with its own mechanism for disrupting the native function of β-defensin 40. Research in this area often focuses on fine-tuning the specificity of these inhibitors to ensure they selectively target β-defensin 40 without affecting other defensins or similar proteins, which is critical for maintaining the integrity of the broader immune response. The study of β-defensin 40 inhibitors continues to be an area of active research, particularly in understanding the broader implications of modulating innate immune components at the molecular level.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor affecting the MAPK pathway. SB202190 indirectly hampers β-defensin 40 by disrupting the p38 MAPK pathway, known to modulate β-defensin 40 expression through specific transcription factors. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor disrupting PI3K/AKT signaling. Wortmannin indirectly suppresses β-defensin 40, as PI3K/AKT signaling regulates β-defensin 40 transcription through specific transcription factors. | ||||||
Filgotinib | 1206161-97-8 | sc-507393 | 10 mg | $150.00 | ||
JAK1 inhibitor affecting JAK-STAT signaling. Filgotinib indirectly influences β-defensin 40 by blocking JAK-STAT signaling, crucial for the activation of transcription factors involved in β-defensin 40 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor influencing the MAPK/ERK pathway. PD98059 indirectly influences β-defensin 40 expression by disrupting the MAPK/ERK pathway, which modulates β-defensin 40 transcription through specific downstream effectors. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor disrupting PI3K/AKT signaling. LY294002 indirectly hinders β-defensin 40, as PI3K/AKT signaling is implicated in the regulation of β-defensin 40 transcription by modulating specific transcription factors. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
MEK inhibitor influencing the MAPK/ERK pathway. Selumetinib indirectly influences β-defensin 40 expression by disrupting the MAPK/ERK pathway, which modulates β-defensin 40 transcription through specific downstream effectors. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the AP-1 pathway. SP600125 indirectly hampers β-defensin 40, as the AP-1 transcription factor, downstream of JNK, is involved in the transcriptional regulation of β-defensin 40. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
HDAC inhibitor modulating chromatin structure. Vorinostat indirectly suppresses β-defensin 40 by altering histone acetylation, influencing the accessibility of the β-defensin 40 gene for transcription. | ||||||
PI3K/HDAC Inhibitor | 1339928-25-4 | sc-364584 sc-364584A | 5 mg 10 mg | $347.00 $471.00 | ||
PI3K/HDAC Inhibitor indirectly influences β-defensin 40 by targeting both HDAC and PI3K, impacting histone acetylation and PI3K/AKT signaling, respectively, both implicated in the regulation of β-defensin 40 transcription through specific transcription factors. | ||||||
12β-Hydroxydigitoxin | 20830-75-5 | sc-213604 sc-213604A | 1 g 5 g | $143.00 $694.00 | ||
Inhibitor of Na+/K+-ATPase. 12β-Hydroxydigitoxin indirectly inhibits β-defensin 40 by modulating intracellular calcium levels, which influence the activity of transcription factors involved in β-defensin 40 expression. | ||||||